Patent ID: 7671022
Filing Date: 2010-03-02
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating a cardiovascular disease comprising administering to a subject an effective amount of a soluble CTLA4 mutant molecule comprising an extracellular domain of a CTLA4 molecule, or portion thereof which binds a B7-1 or B7-2 antigen expressed on activated B cells, wherein the extracellular domain of the CTLA4 mutant molecule comprises the amino acids shown in FIG. 23 beginning with methionine at position +1 or with alanine at position −1 and ending with aspartic acid at position 124 and comprises a mutation in the extracellular domain of a CTLA4 molecule, wherein the cardiovascular disease is selected from the group consisting of: atherosclerosis; coronary heart disease (CHD); restensosis; peripheral arterial disease; coronary bypass grafting surgery; carotid artery disease; arteritis; myocarditis; unstable angina (UA); unstable refractory angina; stable angina (SA); chronic stable angina; acute coronary syndrome (ACS); myocardial infarction; acute myocardial infarction (AMI), including first or recurrent myocardial infarction, non-Q wave myocardial infarction, non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction.